{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04207320",
            "orgStudyIdInfo": {
                "id": "IRB19-0640"
            },
            "organization": {
                "fullName": "University of Chicago",
                "class": "OTHER"
            },
            "briefTitle": "Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Severe Sickle Cell Disease",
            "officialTitle": "Hematopoietic Stem Cell Transplantation for Patients With Severe Sickle Cell Disease Using Myeloablative Conditioning and \u03b1\u03b2+ T-cell Depleted Hematopoietic Stem Cells From Partially Matched Familial Donors",
            "therapeuticArea": [
                "Other"
            ],
            "study": "haploidentical-hematopoietic-stem-cell-transplantation-hsct-for-patients-with-severe-sickle-cell-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-04-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-12-11",
            "studyFirstSubmitQcDate": "2019-12-19",
            "studyFirstPostDateStruct": {
                "date": "2019-12-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-05-11",
            "lastUpdatePostDateStruct": {
                "date": "2023-05-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Chicago",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to develop a safe and curative stem cell transplant approach to treating sickle cell disease by assessing the safety of haploidentical hematopoietic stem cell transplantation using \u03b1\u03b2+ T-cell depletion for children and adolescents with severe sickle cell disease (SCD)."
        },
        "conditionsModule": {
            "conditions": [
                "Sickle Cell Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 38,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Stage I",
                    "type": "EXPERIMENTAL",
                    "description": "Stage I will include eligible subjects between the ages of 10-25 years.",
                    "interventionNames": [
                        "Device: \u03b1\u03b2+ T-cell depletion with Miltenyi CliniMACS system"
                    ]
                },
                {
                    "label": "Stage II",
                    "type": "EXPERIMENTAL",
                    "description": "Stage II will include eligible subjects between the ages of 2-25 years.",
                    "interventionNames": [
                        "Device: \u03b1\u03b2+ T-cell depletion with Miltenyi CliniMACS system"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DEVICE",
                    "name": "\u03b1\u03b2+ T-cell depletion with Miltenyi CliniMACS system",
                    "description": "Haploidentical CD34+ megadose hematopoietic stem cell transplant in which cells are purified using the Miltenyi CliniMACS system designed for \u03b1\u03b2+ T-cell receptor selection using immunomagnetic beads.",
                    "armGroupLabels": [
                        "Stage I",
                        "Stage II"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety, as measured by incidence of graft failure, grade III/IV irreversible end organ toxicity, grade III/IV aGvHD, or death within 100 days post-Hap-HSCT",
                    "description": "Graft Function: efficacy is defined as stable donor engraftment (\\>5% total nucleated cell DNA) and donor erythropoiesis that corrects the SCD hematologic phenotype (\\<50% HbS in the peripheral blood).\n\nOrgan Toxicity: grade III/IV irreversible end organ toxicity based on NCI grading\n\nGraft Versus Host disease: grade III/IV aGvHD or death within 100 days post- Hap-HSCT",
                    "timeFrame": "100 days post-Hap-HSCT"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Estimate 1-year overall and event-free survival after Hap-HSCT",
                    "description": "Proportion of patients at 1 year who have not died or had graft failure",
                    "timeFrame": "1 year post transplant"
                },
                {
                    "measure": "Observe the incidence of grades I through IV acute GvHD",
                    "description": "Proportion of subjects with grades I through IV acute GvHD",
                    "timeFrame": "100 days post transplant"
                },
                {
                    "measure": "Observe incidence of severe acute GvHD as defined by grades III through IV",
                    "description": "Proportion of subjects with grades III through IV acute GvHD",
                    "timeFrame": "100 days post transplant"
                },
                {
                    "measure": "Observe the incidence of grades I through IV chronic GvHD",
                    "description": "Proportion of subjects with grades I through IV chronic GvHD",
                    "timeFrame": "1 year post transplant"
                },
                {
                    "measure": "Observe incidence of severe chronic GvHD as defined by grades III and IV",
                    "description": "Proportion of subjects with grades III through IV chronic GvHD",
                    "timeFrame": "1 year post transplant"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Hemoglobin SS, SC, S-\u03b20 Thalassemia, or SO-Arab Sickle Cell Disease\n* Between the ages of 2 and 25 years (Stage 1: 10-25 years; Stage II: 2-25 years)\n* Lack a fully matched family donor or fully matched unrelated donor register in the National Marrow Donor Program\n* Partially-matched family member with hemoglobin AA (normal) or hemoglobin AS (sickle trait) phenotype\n* SCD with Severe Phenotype, defined by the following criteria: Neurologic manifestations of sickle disease including cerebral vascular accident (CVA), transient ischemic event (TIA) or abnormal MRI findings suggestive of silent infarct; Two or more episodes of acute chest syndrome (ACS) requiring admission for transfusional or respiratory support including supplemental oxygen within \\[two years\\] of enrollment in study despite hydroxyurea therapy. Patients who cannot tolerate hydroxyurea and who experience multiple episodes of ACS will also be eligible; History of severe vaso-occlusive (VOC) disease requiring hospitalization and intravenous narcotics on 3 or more occasions per year over the two years prior to enrollment despite hydroxyurea therapy. Patients who cannot tolerate hydroxyurea and who experience multiple episodes of VOC will also be eligible; Other severe phenotype as evidenced by end organ dysfunction related to sickle cell disease.\n\nExclusion Criteria:\n\n* Karnofsky or Lansky score \\< 60%\n* Acute hepatitis or evidence of moderate or severe portal fibrosis on biopsy. (Biopsy will be obtained if patient has been on chronic transfusion therapy \\> 6 months or has a ferritin \\> 1000 ng/ml) or AST or ALT \\>5 times the upper limit of normal\n* Severe renal impairment (as evidenced by creatinine clearance of \\<50ml/minute glomerular filtration rate (GFR) \\< 50% predicted normal)\n* Cardiac function that demonstrates shortening fraction less than 26% by cardiac echocardiogram or pulmonary hypertension.\n* Pregnant Female.\n* Lactating female.\n* Pulmonary function with baseline O2 saturation \\<85% or Diffusing Capacity for Carbon Monoxide (DLCO) on pulmonary function testing (PFT) with a DLCO \\<40%.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "2 Years",
            "maximumAge": "25 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Rebecca Puplava",
                    "role": "CONTACT",
                    "phone": "773-702-2879",
                    "email": "rpuplava@peds.bsd.uchicago.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "John Cunningham, MD",
                    "affiliation": "University of Chicago",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "The University of Chicago",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60637",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Shelby Gruntorad, MS",
                            "role": "CONTACT",
                            "phone": "773-702-6554",
                            "email": "sgruntorad@peds.bsd.uchicago.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000755",
                    "term": "Anemia, Sickle Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000745",
                    "term": "Anemia, Hemolytic, Congenital"
                },
                {
                    "id": "D000000743",
                    "term": "Anemia, Hemolytic"
                },
                {
                    "id": "D000000740",
                    "term": "Anemia"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006453",
                    "term": "Hemoglobinopathies"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4085",
                    "name": "Anemia, Sickle Cell",
                    "asFound": "Sickle Cell Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4070",
                    "name": "Anemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M9547",
                    "name": "Hemolysis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4073",
                    "name": "Anemia, Hemolytic",
                    "relevance": "LOW"
                },
                {
                    "id": "M4075",
                    "name": "Anemia, Hemolytic, Congenital",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9539",
                    "name": "Hemoglobinopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "T5229",
                    "name": "Sickle Cell Anemia",
                    "asFound": "Sickle Cell Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}